You’ve probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss and diabetes. Now, researchers are investigating whether these medications known as GLP-1 agonists or GLP-1 drugs could treat everything from cancer and brain disease to depression, addiction and endometriosis. Some findings are genuinely exciting. Others are being oversold. Here’s what the science actually says. First, how do these drugs work? GLP-1 (glucagon-like peptide-1) is a hormone your […]

Read more

Oral semaglutide (Wegovy, Novo Nordisk) tablets for weight loss have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). In a statement published on 11 June 2026, the MHRA said that the drug — the first oral glucagon-like peptide-1 (GLP-1) available in the UK — can be used in adults with obesity, who have a BMI of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one […]

Read more

Popular GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have already transformed the treatment of type 2 diabetes and obesity. Now, new research suggests these medications may also help prevent and treat addiction across a broad range of substances. Researchers at Washington University School of Medicine in St. Louis found that GLP-1 medications were associated with lower risks of developing substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other substances. The drugs were also linked […]

Read more

NEWYou can now listen to Fox News articles! Among those taking GLP-1 medications for weight loss, exercise rates are decreasing, according to new research. The study, set to be presented at ENDO 2026 (the Endocrine Society’s annual meeting) in Chicago this week, found that adults with obesity who lost weight with a GLP-1, such as Ozempic or Wegovy, “significantly reduced” their physical activity. In an Endocrine Society press release, study lead Sajana Maharjan, MD, of HSHS St. […]

Read more

Weight-loss jabs are the latest craze for shedding a few pounds. Their effect has been dramatic with drugs such as Ozempic and Wegovy (semaglutide) causing users to lose up to 15% of their body fat on average. Semaglutide, which is a glucagon-like peptide 1 (GLP-1 receptor agonist drug), mimics the action of a natural gut hormone which is released after we eat. This gut hormone triggers multiple physiological responses that play a role in regulating body weight, […]

Read more

Some Medicare patients will be able to access to GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more affordable.  Called Medicare GLP-1 Bridge, the pilot program expands access to weight-loss drugs made by Eli Lilly and Novo Nordisk, including Zepbound, Foundayo and Wegovy. “Medicare is not changing the law right now,” said Juliette Cubanski, vice president and director of […]

Read more

Share on PinterestResearchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty Images A meta-analysis found that one type of GLP-1 medication may be more effective than others. The analysis showed that GLP-1s containing tirzepatide (Zepbound, Mounjaro) helped people lose more weight than those containing semaglutide (Ozempic, Wegovy). Liraglutide (Saxenda) had the lowest weight loss percentage among users. The success of tirzepatide may be due to its dual […]

Read more

If the man hadn’t come into the hospital, Komolafe said the consequences could have been serious. “In these instances, we are most concerned about complications from rapid depletion of fluid and electrolytes. This can lead to various complications including acute kidney injury, low potassium levels, which predispose to abnormal heart rhythms, and low blood sodium levels, which can cause mental status alterations, including coma, when severe.” Before coming to the hospital, the man had been having bowel […]

Read more

All studies were conducted according to all relevant ethical regulations and principles of the Declaration of Helsinki. UKB was granted ethical approval from the North West Centre for Research Ethics Committee (11/NW/0382), in the form of a Research Tissue Bank (RTB) approval. The EPIC-Norfolk study has been approved by the Norfolk Research Ethics Committee, under the reference number 05/Q0101/191. G&H was approved by the London Southeast NRES Committee of the Health Research Authority (14/LO/1240). SURMOUNT-1 was conducted […]

Read more

DEERFIELD, Ill., February 26, 2026 – Walgreens announced today the launch of Walgreens Weight Management, a new digital healthcare offering designed to help eligible adults access personalized, clinician-guided support for weight loss. This expands Walgreens’ Virtual Healthcare platform and provides patients with convenient access to licensed doctors and nurse practitioners, FDA-approved medication options and ongoing support from the comfort of their home. The program is intended for eligible overweight and obese adults ages 18-64 who plan to […]

Read more